Astria Therapeutics to Join 2024 Wedbush PacGrow Healthcare Conference

BOSTON-- Astria Therapeutics, Inc. (Nasdaq: ATXS), a biopharmaceutical company devoted to developing transformative treatments for allergic and immunological diseases, announced its involvement in an upcoming panel at the 2024 Wedbush PacGrow Healthcare Conference. The conference is scheduled to take place on August 14 in New York, NY.

Dr. Jill C. Milne, the Chief Executive Officer of Astria Therapeutics, will represent the company in a discussion panel named, “HAE Ya! The Changing Face of the HAE Therapeutic Landscape.” This session is set for Wednesday, August 14, at 2:30 pm ET. The panel will focus on hereditary angioedema (HAE), a rare genetic disorder characterized by severe swelling in various body parts, including the extremities, face, intestinal tract, and airway.

Astria Therapeutics is committed to offering innovative solutions to individuals and families dealing with allergic and immunological conditions. The company's primary initiative, STAR-0215, is currently in clinical development. STAR-0215 is a monoclonal antibody designed to inhibit plasma kallikrein, an enzyme that plays a significant role in the pathology of hereditary angioedema. By targeting this enzyme, STAR-0215 aims to provide a more effective treatment option for patients suffering from this debilitating condition.

In addition to STAR-0215, Astria Therapeutics is also working on STAR-0310, another monoclonal antibody. This program is in the preclinical development stage and aims to treat atopic dermatitis by acting as an OX40 antagonist. OX40 is a crucial receptor in the immune system that can contribute to the inflammation and persistent symptoms seen in atopic dermatitis. By inhibiting this receptor, STAR-0310 seeks to alleviate the chronic and often severe symptoms of this skin disorder.

Astria Therapeutics embraces a mission that goes beyond merely treating diseases; the company strives to make a significant impact on the lives of patients and their families. The focus is not just on the scientific and clinical aspects of drug development but also on understanding and addressing the real-world challenges faced by those living with these conditions.

The upcoming panel at the Wedbush PacGrow Healthcare Conference offers an important platform for Astria Therapeutics to discuss advancements in the treatment of hereditary angioedema, share insights from their ongoing research, and engage with other experts in the field. This event is anticipated to foster dialogue that could lead to further innovations and improvements in the therapeutic landscape for HAE and other allergic and immunological diseases.

Astria Therapeutics continues to advance its clinical and preclinical programs with the goal of bringing new, life-changing therapies to market, emphasizing their commitment to improving patient outcomes and addressing unmet medical needs.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!